Results 101 to 110 of about 150,839 (152)

Remodeling the Inflammatory Microenvironment: Nanomaterial-Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis. [PDF]

Small Sci
Zhou C, Li J, Zhang J, Wang H, Lu H, Shang S, Li W.   +6 more
europepmc   +1 more source

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. [PDF]

Nat Commun
Ostendorf L, Zernicke J, Klotsche J, Kempkens R, Beenken AE, Biesen R, Cheng Q, Khodadadi L, Guerra GM, Heinrich F, Durek P, Burmester GR, Krönke G, Hiepe F, Mashreghi MF, Alexander T.   +15 more
europepmc   +1 more source

Obinutuzumab in systemic lupus erythematosus: a real-world experience. [PDF]

Front Immunol
Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H, Fu Q.   +10 more
europepmc   +1 more source

Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus. [PDF]

Int J Mol Sci
Palazzo L, Tsoi A, Nikolopoulos D, Parodis I.   +3 more
europepmc   +1 more source

Mapping the plasma proteomic architecture of systemic lupus erythematosus

Leung GHD, Bottomley C, Buang N, Maughan RT, Whittle BJ, Zeidaabadi B, Huang Y, Turner-Stokes T, Condon M, Lightstone L, Cairns T, Botto M, Pickering MC, Peters JE.   +13 more
europepmc   +1 more source

Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection. [PDF]

RMD Open
Trefond L, Mathian A, Boussouar S, Maloum K, Settegrana C, Lhote R, Pha M, Papo M, Chasset F, Cohen Aubart F, Haroche J, Pereira B, Hie M, Amoura Z.   +13 more
europepmc   +1 more source

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience. [PDF]

Front Immunol
Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H, Fu Q.   +10 more
europepmc   +1 more source